Welcome to our dedicated page for REVIVA PHARMACEUTICALS HOLDINGS SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REVIVA PHARMACEUTICALS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REVIVA PHARMACEUTICALS HOLDINGS's regulatory disclosures and financial reporting.
Reviva Pharmaceuticals Holdings (RVPH) called its 2025 annual meeting for December 18, 2025 at 11:00 a.m. Pacific Time, to be held virtually. Stockholders will vote on electing five directors, ratifying Baker Tilly US, LLP as auditor for 2025, an advisory say‑on‑pay, and two capital-structure items.
The Board seeks approval to increase authorized common shares from 315,000,000 to 515,000,000 and to authorize a reverse stock split of issued common shares at a ratio between 1:2 and 1:20, at any time prior to December 31, 2026, at the Board’s discretion and without further stockholder approval. An adjournment proposal is included if additional solicitation is needed. The Board recommends voting “FOR” all proposals.
Holders of record as of October 21, 2025 may vote; 114,078,619 shares of common stock were outstanding on the record date. Voting can be completed online, by phone, by mail, or during the virtual meeting using a 16‑digit control number.
Reviva Pharmaceuticals Holdings (RVPH) filed a preliminary proxy for its virtual Annual Meeting on December 18, 2025. Stockholders will vote to elect five directors, ratify Baker Tilly US, LLP as auditor, approve an advisory say‑on‑pay, and consider two capital structure items: increasing authorized common stock from 315,000,000 to 515,000,000 and authorizing a reverse stock split at a ratio between 1:2 and 1:20, which the Board may implement at its discretion any time before December 31, 2026. An adjournment proposal is also included.
The Board recommends voting “FOR” all proposals. Only holders of record as of October 21, 2025 may vote; shares outstanding were 114,078,619 as of that date. Director elections use a plurality standard, while the auditor ratification, say‑on‑pay, authorized share increase, reverse split, and adjournment proposals require a majority of votes properly cast. The meeting will be held online at www.virtualshareholdermeeting.com/RVPH2025.
Reviva Pharmaceuticals Holdings (RVPH) reported that Nasdaq confirmed the company has regained compliance with the minimum Market Value of Listed Securities requirement. Nasdaq determined RVPH’s MVLS was $35 million or greater for 10 consecutive business days from September 30, 2025 to October 13, 2025, closing that matter.
The company remains out of compliance with Nasdaq’s $1.00 minimum bid price rule, with an initial 180‑day window to regain compliance until November 10, 2025. Reviva said it will continue monitoring its share price and may consider actions, including a potential reverse stock split, noting there is no assurance it will regain or maintain compliance.
683 Capital Management, LLC, 683 Capital Partners, LP and Ari Zweiman report beneficial ownership of 5,435,000 shares of Reviva Pharmaceuticals Holdings, Inc., representing approximately 5.36% of the company’s common stock on a fully-diluted basis as of September 29, 2025. The stake comprises 450,000 issued shares and 4,985,000 currently exercisable warrants, and the reporting persons note shared voting and dispositive power.
The filing states the position is not held to influence control of the issuer and lists reporting addresses in New York and Delaware organizational details.
Reviva Pharmaceuticals Holdings, Inc. amended its Bylaws on September 26, 2025 to lower the quorum for stockholder meetings from a majority of voting power to one-third (33 1/3%) of the voting power outstanding and entitled to vote, as present in person, by remote communication, or by proxy, except where a higher quorum is required by law or the certificate of incorporation or bylaws. The amendment was approved by the Board and the full text is filed as Exhibit 3.1.
Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.
Amendment No. 11 to the Schedule 13D updates beneficial ownership disclosures for Parag Saxena and Vedanta Partners, LLC in Reviva Pharmaceuticals Holdings, Inc. (ticker RVPH). As of the filing date, Vedanta Partners reports beneficial ownership of 5,367,069 shares, representing 5.4% of the 96,337,119 shares outstanding. Mr. Saxena is deemed to beneficially own 6,259,806 shares, or 6.2%, including directly held shares, shares held through related partnerships, vested options and securities underlying warrants and pre-funded warrants. The filing states no transactions occurred in the prior 60 days and explains certain exercise limitations on warrants that prevent ownership above 4.99% for some holders.
Reviva Pharmaceuticals Holdings, Inc. filed a Current Report disclosing that on September 18, 2025 it launched and priced an offering of securities and entered into a Placement Agency Agreement with A.G.P./Alliance Global Partners to market the offering. The company agreed to pay the placement agent a cash fee equal to 7.0% of aggregate gross proceeds (with a 3.5% fee for proceeds from certain investors as mutually agreed) and to reimburse up to $15,000 for non-accountable expenses and up to $75,000 for out-of-pocket accountable legal expenses. The filing references executed forms of Series E and Series F warrants, a securities purchase agreement, the placement agency agreement, legal opinion of Lowenstein Sandler LLP, and press releases announcing the launch and pricing of the offering as exhibits.
The report includes a forward-looking statement caution noting risks to closing the offering and to anticipated proceeds; the filing does not state the final offering size or the exact proceeds expected in this Current Report text.
Reviva Pharmaceuticals Holdings is conducting a primary offering of 27,000,000 shares of common stock, together with Series E warrants for up to 27,000,000 shares and Series F warrants for up to 27,000,000 shares, at a combined public offering price of $0.335 per share and accompanying warrants, for maximum gross proceeds of $9,045,000. After placement fees and expenses, net proceeds are estimated at about $8.1 million, with the company planning to use the cash for research and development of its lead drug brilaroxazine and for working capital.
The offering is a best-efforts, no-minimum deal led by A.G.P., so Reviva may raise substantially less than the maximum and investor funds will not be placed in escrow. Common shares outstanding would be 96,337,119 after the transaction, before any warrant exercises, resulting in dilution for new and existing holders. The Series E warrants are exercisable immediately at $0.335 for five years, while the Series F warrants share the same exercise price with a 12‑month term.
Reviva highlights positive Phase 3 RECOVER-1 data and one‑year open‑label extension results in schizophrenia and plans to seek an FDA meeting in Q4‑2025 to discuss a potential NDA based on existing trials, with a possible NDA filing targeted for Q2‑2026 if the agency response is favorable and additional financing is secured.
Reviva Pharmaceuticals plans a primary offering of common stock, together with Series E and Series F common warrants, and pre-funded warrants sold in lieu of common stock for certain large investors. Each share or pre-funded warrant will be sold with one Series E warrant and one Series F warrant, both exercisable immediately, with the Series E warrant having a five-year term and the Series F warrant a 12‑month term. The transaction is a best‑efforts, no‑minimum offering led by A.G.P./Alliance Global Partners, so proceeds to Reviva will depend on actual investor demand.
Reviva expects to use net proceeds mainly to fund research and development for its lead drug brilaroxazine and for working capital and general corporate purposes. The prospectus highlights positive Phase 3 RECOVER-1 and one‑year open‑label extension results in schizophrenia and outlines a potential path to an NDA submission based on existing Phase 2 and Phase 3 data. The company cautions that investors may face dilution, that the warrants will not be listed, and that limited proceeds could constrain its ability to execute its business plan.